Abstract Library

#2974 MEK/RAF and PARP as Novel Targets in Neuroendocrine Neoplasms – First Results from a Molecular in vitro Tumor Board

Introduction: Neuroendocrine neoplasms (NEN) are a heterogeneous group comprising well differentiated neuroendocrine tumors (NET) and poorly differentiated neuroendocrine carcinomas (NEC). Although, major progress has been made in the development of targeted therapies in various cancers, establishment of a promising personalized therapy in NEN is still pending. So far, a lack of suitable preclinical models represent a major challenge concerning the validation of a mutational based targeted therapy (MBTT)

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Viol F, Sipos B, Amin T, Fahl M, Grabowski P,

Keywords: Neuroendocrine neoplasms, Personalized therapy, Preclinical in vitro models, Mutational based targeted therapy,

#2869 Sunitinib in Combination with Lanreotide for the Treatment of Pancreatic Neuroendocrine Tumors

Introduction: A 33-year-old patient with pancreatic neuroendocrine tumor (NET) G2 revealed progression of the disease in the form of multiple metastases to the liver, lymph nodes of the hepatoduodenal ligament and retroperitoneal space 1.5 months after surgical treatment.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Markovich A, Kuznetsova A, Emelianova G, Dronova E,

Keywords: neuroendocrine tumor, pancreas, sunitinib, somatostatin analogues,

#2723 Achieving Objective Response in Treatment of Non-Resectable Neuroendocrine Tumors Does Not Predict Longer Time to Progression Compared to Achieving Stable Disease

Introduction: There are several treatment modalities for unresectable neuroendocrine tumors. Traditionally the goal of these treatments are to reduce the tumor load; objective response (OR). Less emphasis has been put on inducing the tumors to stop growing without reduction in total tumor load; stable disease (SD).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Thiis-Evensen E

Authors: Thiis-Evensen E, Sponheim J,

Keywords: Neuroendocrine tumor, Treatment, Radiology, Time to progression,

#2265 Activity of Bevacizumab in Neuroendocrine Neoplasms

Introduction: The combination of the anti-VEGF antibody bevacizumab (BEV) with a multitude of other antineoplastic substances has shown promising activity in neuroendocrine neoplasms (NEN). However, data proving the superiority of BEV-containing vs. BEV-free protocols are lacking.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Apostolidis L

Authors: Fejzibegovic N, Jäger D, Winkler E, Apostolidis L,

Keywords: neuroendocrine neoplasm, targeted therapy, bevacizumab, antiangiogenesis,

#2112 Relationship between Metabolic Toxicity and Efficacy of Everolimus in Patients with Neuroendocrine Tumors (NETs): A Pooled Analysis from the Randomized, Phase 3 RADIANT-3 and RADIANT-4 Trials

Introduction: Hyperglycemia and hypercholesterolemia are class effects of mTOR inhibitors such as everolimus (EVE).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Fazio N, Carnaghi C, Buzzoni R, Valle J, Herbst F,

Keywords: adverse events, everolimus, RADIANT-3, RADIANT-4, landmark analysis, mTOR inhibitors, targeted therapy, neuroendocrine tumors,